CosmopolitanCovid DiariesJust In

Serum Institute of India signs deal with US firm Novavax for COVID-19 vaccine supply

Nisha Agarwal

American vaccine developer Novavax Inc. has entered into a supply and license agreement with Pune-headquartered Serum Institute of India (SII). According to the Maryland-headquartered Novavax’s filing in the US Securities and Exchange Commission (SEC), the deal between the two companies was signed on July 30 for the “development, co-formulation, filling and finishing, registration and commercialization” of its COVID-19 vaccine candidate, NVX-CoV2373.

Novavax reported on Tuesday that its vaccine candidate had successfully produced antibodies against the coronavirus during early stage human trials.

According to the agreement, the Serum Institute will get exclusive rights for the supply of vaccine in India and non-exclusive rights in all countries except those in the upper-middle or high-income groups during the ‘pandemic period’. After the pandemic period, SII will be able to supply the vaccine in low and middle-income groups.

Under the agreement, SII would purchase two components of the vaccine, namely- the antigen drug substance and Novavax’s trademarked adjuvant (which is a component added to the vaccine to produce more antibodies in those who have been injected with it).

Both the parties will split the revenue equally generated from sale of the product in its licensed territory as mentioned in the filing. SII will exercise “commercially responsible efforts to develop and obtain regulatory approval” for the vaccine in countries pertaining to its licensed territory. The deal will expire on a country-by-country basis 15 years from its first commercial sale in those countries. After expiration, SII will retain a “fully paid, non-exclusive license” that will permit it to proceed with its manufacturing and commercialization rights on a country-by-country basis within its licensed territory.

Novavax has also expressed that it could start a large pivotal phase III trial of the vaccine as soon as late September and produce 1 billion to 2 billion doses of the vaccine by 2021.

Last week, SII had also received an approval from the Drug Controller General of India to conduct phase II and III human trials of the COVID-19 vaccine candidate developed by Oxford University and British-Swedish pharmaceutical firm AstraZeneca. The Serum Institute is also engaged in developing a vaccine with another American firm, Codagenix although this vaccine is still in the pre-clinical stage.

Researchers across the globe are racing to decode a coronavirus vaccine for public use amid rising cases worldwide. The coronavirus has infected more than 1.87 crore people globally and has claimed 7,06,041 lives. India has reported 19, 64, 536 cases and more than 40,000 deaths so far, making it to the world’s third worst-affected country.

Also Read: 8 killed in a massive fire at a COVID hospital in Ahmedabad

Comments (3)

  1. […] READ ALSO; Vivo not to sponsor IPL 2020; BCCI looks for possible replacement […]

  2. […] Also Read: Serum Institute of India signs deal with US firm Novavax for COVID-19 vaccine supply […]

  3. […] Corona-antidote made by India will be given to Bangladesh on priority basis. The news was announced by Foreign Secretary Harshvardhan Sringla after a meeting with Bangladesh Foreign Secretary Masud bin Momen on the second day of his visit to Dhaka on Wednesday. “India is the world’s leading producer of vaccines,” he said. Eighty percent of the world’s vaccines are made in India. India will not skimp on giving coronavirus vaccines to friends and allies. Naturally, Bangladesh is on the priority list in this regard. ”The Foreign Secretary of Bangladesh also said that they have promised any kind of cooperation to India in the trial of the vaccine. During her second visit to Bangladesh on Tuesday, Sringla met Prime Minister Sheikh Hasina. According to foreign ministry sources, the two sides also exchanged views on regional security, the challenges facing the new world order in the post-Corona situation, in addition to the two countries’ experiences in corona-resistance. Arriving in Dhaka, Sringla said he had gone on a visit as a special envoy of Prime Minister Narendra Modi. “It’s a message to move friendship and relationships forward even in this covid situation.” Communication between friends has become limited during the Corona period. ‘’ was said by Modi to Sringla . Sringla, who took over as India’s High Commissioner to Bangladesh just a few years ago, said his visit was very satisfactory. He said research in Oxford, Britain, was leading in the race for the corona vaccine in the world. Not only is it being tested in India, the Indian company Serum will also produce it. Again, Indian vaccine research is not far behind. Whatever happens first, India will give it to Bangladesh first. Bangladesh Foreign Secretary Masood said Foreign Minister Abdul Momen would chair the meeting of the two countries’ Joint Advisory Commission in Delhi. He will also have to go to Delhi to prepare for the meeting. The promise made by India to give corona vaccine is very necessary for Bangladesh. On the first day of the new year, India will get temporary membership in the Security Council. Bangladesh has expressed its support in this regard. Dhaka wants India to raise the issue of repatriation of Rohingya refugees in the Security Council.They have filed the petition with Delhi. In addition, Sringla has proposed the launch of an air bubble between the two countries. Masood said that they are considering it very seriously. According to foreign ministry sources, India has already launched this ‘air bubble’ communication system with Germany, France, the United Arab Emirates and the Maldives. If it is introduced, Bangladeshi patients will get priority to go to India even under this regulated system, Indian advisers of various projects in Bangladesh will also be able to return to Dhaka. Direct air travel to and from third countries is called ‘air bubble’ communication. In this case, no transit passenger is picked up. Also Read | Serum Institute of India signs deal with US firm Novavax for COVID-19 vaccine supply […]

Comment here